Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 17c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.43 --0%
Revenue Growth %: +24.1%
Financial Fact:
Product sales: 38.48M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +24.1%
Financial Fact:
Product sales: 38.48M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.46), $0.17 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $52.59 million versus the consensus estimate of $55.1 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2025 revenue of $210-250 million, versus the consensus of $227.7 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verizon and Corning reach multi-billion fiber supply deal
- Ionis Pharmaceuticals (IONS) PT Lowered to $54 at BMO Capital Post Pelacarsen Failure
- Piper Sandler Reiterates Overweight Rating on Tyra Biosciences (TYRA) Ahead of Dabo IR NMIBC Readout
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
